When do biologic drug patents expire and when will biosimilars launch?

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Ag	CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN	immune globulin intravenous (human)	For Injection	102367	07/27/2000	⤷ Try a Trial	2031-11-28
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	07/26/2007	⤷ Try a Trial	2031-11-28
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	10/02/2009	⤷ Try a Trial	2031-11-28
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	02/07/2013	⤷ Try a Trial	2031-11-28
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	09/17/2009	⤷ Try a Trial	2031-11-28
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	02/06/2017	⤷ Try a Trial	2031-11-28
Csl Behring Ag	HIZENTRA	immune globulin subcutaneous (human), 20% liquid	Injection	125350	03/04/2010	⤷ Try a Trial	2031-11-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Title:	Method for producing human monoclonal immunoglobuling antibodies
Abstract:	The present invention a method for producing a human immunoglobulin G (IgG) antibody using a prime-boost regime in a Bone Marrow Liver Thymic (BLT) mouse.
Inventor(s):	North; William G. (Hanover, NH), Fiering; Steven N. (Orange, NH)
Assignee:	Trustees of Dartmouth College (Hanover, NH)
Application Number:	14/358,464
Patent Claims:	1. A method for producing a human immunoglobulin G (IgG) antibody comprising (a) subcutaneously administering a prime dose of a peptide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4 mixed with alum or complete Freund's adjuvant to a Bone Marrow Liver Thymic (BLT) mouse; (b) subcutaneously administering a first boost of the peptide at least three weeks after the immunization of (a); (c) subcutaneously administering a second boost of the peptide at least three weeks after the first boost of (b) so that a human IgG is produced to the peptide. 2. The method of claim 1, further comprising mixing spleen cells of the immunized and boosted BLT mouse with an immortal human cell line to produce a hybridoma. 3. The method of claim 1, further comprising the step of sacrificing the BLT mouse four to seven days after the second boost.

Claims for Patent: 9,944,692